PriceTargets.com logo

Cannara Biotech - LOVE Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $3.25
  • Forecasted Upside: ∞
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 07/10/2020 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for LOVE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cannara Biotech Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LOVE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LOVE

Analyst Price Target is $3.25
▲ +∞ Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Cannara Biotech in the last 3 months. The average price target is $3.25, with a high forecast of $3.25 and a low forecast of $3.25. The average price target represents a ∞ upside from the last price of $0.00.

This chart shows the closing price for LOVE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Cannara Biotech.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/2/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/1/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/1/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2026
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2026

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
2/24/2026TD SecuritiesSet TargetBuy$3.25
(Data available from 2/24/2021 forward)

News Sentiment Rating

0.83 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/29/2025
  • 5 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/28/2025
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2025
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2025
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
11/26/2025
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2025
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2026
  • 4 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2026

Current Sentiment

  • 4 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Cannara Biotech logo
Cannara Biotech Inc. is a vertically integrated cannabis company building the largest indoor cannabis cultivation facility in Quebec, a modern and secure 625,000 square foot facility. Leveraging Quebec's low electricity costs, Cannara will produce high-grade indoor cannabis, specializing in derivative products and brands.
Read More

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

69,070 shs

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Cannara Biotech?

The following Wall Street sell-side analysts have issued research reports on Cannara Biotech in the last year: TD Securities.
View the latest analyst ratings for LOVE.

What is the current price target for Cannara Biotech?

0 Wall Street analysts have set twelve-month price targets for Cannara Biotech in the last year. Their average twelve-month price target is $3.25. TD Securities has the highest price target set, predicting LOVE will reach $3.25 in the next twelve months. TD Securities has the lowest price target set, forecasting a price of $3.25 for Cannara Biotech in the next year.
View the latest price targets for LOVE.

What is the current consensus analyst rating for Cannara Biotech?

Cannara Biotech currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LOVE will outperform the market and that investors should add to their positions of Cannara Biotech.
View the latest ratings for LOVE.

What other companies compete with Cannara Biotech?

Other companies that are similar to Cannara Biotech include Abattis Bioceuticals, Agraflora Organics International, Amplify Alternative Harvest ETF, Bio-Rad Laboratories and Blueberries Medical. Learn More about companies similar to Cannara Biotech.